Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Savient Suggests More Restrictive REMS Plan For Pegloticase In BLA Amendment

This article was originally published in The Pink Sheet Daily

Executive Summary

PDUFA date shifts to July 30; FDA to reschedule advisory committee.
Advertisement

Related Content

Savient's Gout Therapy Krystexxa Delayed At FDA.
Savient's Gout Therapy Krystexxa Delayed At FDA.
Savient's Gout Therapy Krystexxa Delayed At FDA
Savient's Gout Therapy Krystexxa Delayed At FDA
Approvals & Regulatory Updates, In Brief
Approvals & Regulatory Updates, In Brief
Takeda Positions Uloric To Gout Patients In Need Of Better Control
Takeda Positions Uloric To Gout Patients In Need Of Better Control
Takeda Uloric Cleared For Gout Indication
Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?

Topics

Advertisement
UsernamePublicRestriction

Register

PS068994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel